Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

If you’re looking for an OTC medication that’ll ease pain and quell inflammation, there are several great options to choose ...

Bayer now says it expects to make €3 billion ... results of the phase 3 ARASENS trial in the New England Journal of Medicine. The study showed that adding Nubeqa to standard therapy with anti ...

Since becoming Bayer's CEO, Bill Anderson has introduced striking changes to the company, including an overhaul of its budget system, which he sees as the driving source of corporate bureaucracy.

Leadership Strategist Dan Pontefract covers leadership and culture. Heike Prinz of Bayer's Board of Management recently articulated the company's predicament, stating, "Bayer is currently in a ...

Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co's rival drug gefapixant.

According to The Wall Street Journal, Bayer started putting in the cotton ... More from Science We've all been there: reaching for the medicine cabinet with a splitting headache, opening the ...

Faced with huge debt, the impending expiry of a crucial patent, and ongoing litigation over a horror acquisition, Bayer CEO Bill Anderson made a bold move a year ago to get his damaged company ...

Bayer cut its full-year earnings target after a tough agricultural market hit its crop-science division, and said it heads ...